Alpha Tau Medical Ltd. (NASDAQ:DRTS) Stock Rated "Hold" by Wall Street Brokerages

Key Points

• Analysts hold a mixed view of Alpha Tau Medical, resulting in a consensus “Hold” rating from eight analysts. The average 12-month price target is $15.40, with targets recently raised by Barclays and HC Wainwright.
• Alpha Tau Medical reported a quarterly loss of $0.50 per share, missing the analyst consensus estimate of a $0.14 loss. Analysts expect a full-year loss of approximately $1.05 per share.
• CFO Raphi Levy sold 17,730 shares for about $248,220 under a pre-arranged trading plan, reducing his stake by 16.43%; corporate insiders collectively own 39.5% of the company.

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) has earned a consensus recommendation of "Hold" from the eight analysts that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $15.40.

DRTS has been the subject of a number of research analyst reports. Zacks Research downgraded shares of Alpha Tau Medical from a "hold" rating to a "strong sell" rating in a research note on Tuesday, September 1st. Benchmark reiterated a "buy" rating on shares of Alpha Tau Medical in a report on Thursday, July 23rd. Barclays raised their target price on shares of Alpha Tau Medical from $17.00 to $30.00 and gave the stock an "overweight" rating in a research report on Thursday, September 3rd. Weiss Ratings reissued a "sell (d-)" rating on shares of Alpha Tau Medical in a research report on Friday, July 17th. Finally, HC Wainwright boosted their target price on shares of Alpha Tau Medical from $15.00 to $16.00 and gave the company a "buy" rating in a report on Tuesday, August 11th.

Insiders Place Their Bets

In other Alpha Tau Medical news, CFO Raphi Levy sold 17,730 shares of Alpha Tau Medical stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $14.00, for a total value of $248,220.00. Following the transaction, the chief financial officer owned 90,180 shares in the company, valued at $1,262,520. This trade represents a 16.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 39.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Alpha Tau Medical

Institutional investors have recently made changes to their positions in the stock. Everhart Financial Group Inc. purchased a new position in shares of Alpha Tau Medical in the 2nd quarter worth $126,000. Renaissance Technologies LLC acquired a new position in Alpha Tau Medical in the first quarter valued at $286,000. Finally, Principal Financial Group Inc. acquired a new position in Alpha Tau Medical in the first quarter valued at $132,000. 2.65% of the stock is owned by hedge funds and other institutional investors.

Alpha Tau Medical Stock Performance

Alpha Tau Medical stock opened at $13.50 on Thursday. The firm has a market capitalization of $1.22 billion, a P/E ratio of -12.98 and a beta of 1.22. The stock has a fifty day moving average price of $14.50 and a 200 day moving average price of $11.60. Alpha Tau Medical has a 52 week low of $3.43 and a 52 week high of $15.79. The company has a current ratio of 11.09, a quick ratio of 7.79 and a debt-to-equity ratio of 0.15.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.36). Equities research analysts anticipate that Alpha Tau Medical will post -1.05 earnings per share for the current year.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is an Israel-based medical technology company focused on developing localized radiation treatments for solid tumors. Its lead technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), is designed to deliver high-energy alpha radiation directly within a tumor while limiting exposure to surrounding healthy tissue.

Alpha DaRT uses implanted radium-224 sources that generate short-lived alpha-emitting atoms. These atoms diffuse through the treated tumor and can damage cancer cells over a localized area.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.